TRPM4 and prostate cancer: Transient receptor potential melastatin‐4 (TRPM4) ion channel expression is upregulated in prostate cancer (PCa), contributing to increased cell proliferation, migration, adhesion, epithelial‐to‐mesenchymal transition, cell cycle shift, and alterations of intracellular Ca2+ signaling.